Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.
about
Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Novel CD28 antagonist mPEG PV1 ...... tivation and IFN-γ production.
@ast
Novel CD28 antagonist mPEG PV1 ...... tivation and IFN-γ production.
@en
type
label
Novel CD28 antagonist mPEG PV1 ...... tivation and IFN-γ production.
@ast
Novel CD28 antagonist mPEG PV1 ...... tivation and IFN-γ production.
@en
prefLabel
Novel CD28 antagonist mPEG PV1 ...... tivation and IFN-γ production.
@ast
Novel CD28 antagonist mPEG PV1 ...... tivation and IFN-γ production.
@en
P2093
P2860
P50
P1433
P1476
Novel CD28 antagonist mPEG PV1 ...... tivation and IFN-γ production.
@en
P2093
Ana Eduarda Zulim de Carvalho
Anna Carla Goldberg
Carina Calixto Jank
Eliana Blini Marengo
Luiz Roberto Sardinha
Luiz Vicente Rizzo
P2860
P304
P356
10.1371/JOURNAL.PONE.0171822
P407
P577
2017-03-01T00:00:00Z